Date published: 2026-7-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

Sec15A CRISPR/Cas9 KO Plasmid (h): sc-405860

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Sec15A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Sec15A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Sec15A CRISPR/Cas9 KO Plasmid (h)

    sc-405860
    20 µg
    $397.00

    Overview

    EXOC6 encodes Sec15A, a core component of the octameric exocyst complex that mediates spatially regulated tethering of secretory vesicles to the plasma membrane prior to SNARE-dependent fusion. Sec15A helps couple RAB and RHO-family GTPase signaling to polarized exocytosis, supporting membrane protein delivery, cell migration, cytokinesis, and epithelial polarity. Through its role in vesicle trafficking and membrane remodeling, EXOC6 is relevant to pathways that shape cell–cell junctions and receptor recycling, processes frequently perturbed in proliferative and invasive cellular phenotypes. Dysregulation of exocyst subunits, including Sec15A, has been associated in the literature with altered secretion programs and signaling outputs in cancer-related and neurodevelopmental contexts, making EXOC6 a useful target for mechanistic studies.

    Sec15A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EXOC6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EXOC6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EXOC6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Sec15A protein expression.

    This CRISPR knockout system enables efficient generation of EXOC6-deficient cell models for investigation of Sec15A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting EXOC6 exon(s) critical for Sec15A function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple EXOC6 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by Sec15A CRISPR/Cas9 KO Plasmid (h) and Sec15A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EXOC6 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by Sec15A HDR Plasmid (h) and Sec15A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EXOC6 homology arms to support homology-directed repair at defined EXOC6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.